Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb:176:106041.
doi: 10.1016/j.phrs.2021.106041. Epub 2021 Dec 22.

Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer

Affiliations
Review

Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer

Seyed Ali Miraghel et al. Pharmacol Res. 2022 Feb.

Abstract

Drug resistance is one of the most critical challenges facing researchers in treating breast cancer. Despite numerous treatments for breast cancer, including conventional chemical drugs, monoclonal antibodies, and immunotherapeutic drugs known as immune checkpoint inhibitors (ICI), many patients resist various approaches. In recent years, the relationship between gene expression profiles and drug resistance phenotypes has attracted much attention. Non-coding RNAs (ncRNAs) are regulatory molecules that have been shown to regulate gene expression and cell transcriptome. Two categories, microRNAs and long non-coding RNAs have been more considered and studied among these ncRNAs. Studying the role of different ncRNAs in chemical drug resistance and ICI resistance together can be beneficial in selecting more effective treatments for breast cancer. Changing the expression and action mechanism of these regulatory molecules on drug resistance phenotypes is the main topic of this review article.

Keywords: Breast cancer; Drug resistance; Immune checkpoint inhibitors; LncRNAs; MicroRNAs; NcRNAs.

PubMed Disclaimer

Substances